Madaan A.,Dabur Research Foundations |
Singh P.,Dabur Research Foundations |
Awasthi A.,Dabur Research Foundations |
Verma R.,Dabur Research Foundations |
And 5 more authors.
Clinical and Translational Oncology | Year: 2013
Introduction: An increasing research interest has been directed toward nanoparticle-based drug delivery systems for their advantages. The appropriate amalgamation of pH sensitivity and tumor targeting is a promising strategy to fabricate drug delivery systems with high efficiency, high selectivity and low toxicity. Materials and Methods: A novel pH sensitive Cremophor-free paclitaxel formulation, Nanoxel™, was developed in which the drug is delivered as nanomicelles using a polymeric carrier that specifically targets tumors. The efficiency and mechanism of intracellular paclitaxel delivery by Nanoxel™ was compared with two other commercially available paclitaxel formulations: Abraxane™ and Intaxel™, using different cell lines representing target cancers [breast, ovary and non-small cell lung carcinoma (NSCLC)] by transmission electron microscopy and quantitative intracellular paclitaxel measurements by high performance liquid chromatography. Results: The data obtained from the present study revealed that the uptake of nanoparticle-based formulations Nanoxel™ and Abraxane™ is mediated by the process of endocytosis and the uptake of paclitaxel was remarkably superior to Intaxel™ in all cell lines tested. Moreover, the intracellular uptake of paclitaxel in Nanoxel™- and Abraxane™-treated groups was comparable. Hence, the nanoparticle-based formulations of paclitaxel (Nanoxel™ and Abraxane™) are endowed with higher efficiency to deliver the drug to target cells as compared to the conventional Cremophor-based formulation. Conclusion: Nanoxel™ appears to be of great promise in tumor targeting and may provide an advantage for paclitaxel delivery into cancer cells. © 2012 Federación de Sociedades Españolas de Oncología (FESEO). Source